Literature DB >> 25754717

Biologic therapies targeting eosinophils: current status and future prospects.

Fanny Legrand1, Amy D Klion2.   

Abstract

The recent explosion in the number of biologic therapies in clinical development for the treatment of eosinophilic disorders is unprecedented. As these agents become available for clinical use, the selection of the most appropriate agent for a given patient will become increasingly complicated. The aims of this review were 2-fold: (1) to present the lessons learned from clinical trials using the first generation of eosinophil-targeted biologics (anti-IL-5 antibodies) and (2) to discuss the advantages and potential limitations of currently available and novel targeted therapies to treat eosinophilic disorders. Published by Elsevier Inc.

Entities:  

Keywords:  Asthma; Benralizumab; Eosinophilic gastrointestinal disorders; Hypereosinophilic syndrome; Mepolizumab; Reslizumab; mAb

Mesh：

Substances：

Year:  2015        PMID： 25754717      PMCID： PMC4418449          DOI： 10.1016/j.jaip.2015.01.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  83 in total

1.  Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8.

Authors:  Ho Jeong Na; Robert G Hamilton; Amy D Klion; Bruce S Bochner
Journal:  J Immunol Methods       Date:  2012-06-06       Impact factor: 2.303

2.  An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.

Authors:  Amal H Assa'ad; Sandeep K Gupta; Margaret H Collins; Mike Thomson; Amy T Heath; Deborah A Smith; Teresa L Perschy; Cynthia H Jurgensen; Hector G Ortega; Seema S Aceves
Journal:  Gastroenterology       Date:  2011-08-09       Impact factor: 22.682

3.  Lebrikizumab treatment in adults with asthma.

Authors:  Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

Review 4.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

Review 5.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

6.  Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Jonathan M Spergel; Marc E Rothenberg; Margaret H Collins; Glenn T Furuta; Jonathan E Markowitz; George Fuchs; Molly A O'Gorman; Juan Pablo Abonia; James Young; Timothy Henkel; H Jeffrey Wilkins; Chris A Liacouras
Journal:  J Allergy Clin Immunol       Date:  2011-12-28       Impact factor: 10.793

7.  IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis.

Authors:  Todd M Wilson; Irina Maric; Juhi Shukla; Margaret Brown; Carlo Santos; Olga Simakova; Paneez Khoury; Michael P Fay; Alexander Kozhich; Roland Kolbeck; Dean D Metcalfe; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2011-07-16       Impact factor: 10.793

8.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

Authors:  Mario Castro; Sameer Mathur; Frederick Hargreave; Louis-Philippe Boulet; Fang Xie; James Young; H Jeffrey Wilkins; Timothy Henkel; Parameswaran Nair
Journal:  Am J Respir Crit Care Med       Date:  2011-08-18       Impact factor: 21.405

9.  Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome.

Authors:  Kristine Herrmann; Wolfgang Ludwig Gross; Frank Moosig
Journal:  Clin Exp Rheumatol       Date:  2012-05-10       Impact factor: 4.473

10.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321
View more
  32 in total

Review 1.  Update on reslizumab for eosinophilic asthma.

Authors:  Juan Carlos Cardet; Elliot Israel
Journal:  Expert Opin Biol Ther       Date:  2015       Impact factor: 4.388

Review 2.  Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma.

Authors:  Leyla Pur Özyiğit; Ayşe Bilge Öztürk; Sevim Bavbek
Journal:  Turk Thorac J       Date:  2020-01-01

3.  Lung Pathologies in a Chronic Inflammation Mouse Model Are Independent of Eosinophil Degranulation.

Authors:  Elizabeth A Jacobsen; Sergei I Ochkur; Alfred D Doyle; William E LeSuer; Wen Li; Cheryl A Protheroe; Dana Colbert; Katie R Zellner; HuaHao H Shen; Charles G Irvin; James J Lee; Nancy A Lee
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

Review 4.  Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

Authors:  Fei Li Kuang; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Nov - Dec

Review 5.  Immune Modulation in Asthma: Current Concepts and Future Strategies.

Authors:  Marek Lommatzsch
Journal:  Respiration       Date:  2020-06-08       Impact factor: 3.580

Review 6.  The eosinophil: For better or worse, in sickness and in health.

Authors:  Bruce S Bochner
Journal:  Ann Allergy Asthma Immunol       Date:  2018-02-27       Impact factor: 6.347

7.  Siglec-7 on peripheral blood eosinophils: Surface expression and function.

Authors:  Fanny Legrand; Nadine Landolina; Ilan Zaffran; Robert O Emeh; Elizabeth Chen; Amy D Klion; Francesca Levi-Schaffer
Journal:  Allergy       Date:  2019-02-26       Impact factor: 13.146

8.  Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.

Authors:  Fanny Legrand; Yun Cao; Joshua B Wechsler; Xiang Zhu; Nives Zimmermann; Shakuntala Rampertaap; Joseph Monsale; Kimberly Romito; Bradford A Youngblood; Emily C Brock; Michelle A Makiya; Nenad Tomasevic; Christopher Bebbington; Irina Maric; Dean D Metcalfe; Bruce S Bochner; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2018-12-10       Impact factor: 10.793

Review 9.  Essential Mechanisms of Differential Activation of Eosinophils by IL-3 Compared to GM-CSF and IL-5.

Authors:  Stephane Esnault; Elizabeth A Kelly
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 10.  The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.

Authors:  Julie K Nguyen; Evan Austin; Alisen Huang; Andrew Mamalis; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2019-09-06       Impact factor: 3.017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.